Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1970 1
1971 1
1975 1
1976 1
1985 1
1987 1
1992 2
1995 2
1998 1
1999 1
2001 2
2002 3
2003 2
2004 3
2005 2
2006 1
2012 1
2013 5
2014 1
2015 4
2016 5
2017 4
2018 9
2019 9
2020 8
2021 16
2022 29
2023 36
2024 28

Text availability

Article attribute

Article type

Publication date

Search Results

165 results

Results by year

Filters applied: . Clear all
Page 1
Blood-based biomarkers for Alzheimer's disease: Current state and future use in a transformed global healthcare landscape.
Hampel H, Hu Y, Cummings J, Mattke S, Iwatsubo T, Nakamura A, Vellas B, O'Bryant S, Shaw LM, Cho M, Batrla R, Vergallo A, Blennow K, Dage J, Schindler SE. Hampel H, et al. Neuron. 2023 Sep 20;111(18):2781-2799. doi: 10.1016/j.neuron.2023.05.017. Epub 2023 Jun 8. Neuron. 2023. PMID: 37295421 Review.
Timely detection of the pathophysiological changes and cognitive impairment caused by Alzheimer's disease (AD) is increasingly pressing because of the advent of biomarker-guided targeted therapies that may be most effective when provided early in the disease. ...
Timely detection of the pathophysiological changes and cognitive impairment caused by Alzheimer's disease (AD) is increasingly pressi …
Gut microbiome composition may be an indicator of preclinical Alzheimer's disease.
Ferreiro AL, Choi J, Ryou J, Newcomer EP, Thompson R, Bollinger RM, Hall-Moore C, Ndao IM, Sax L, Benzinger TLS, Stark SL, Holtzman DM, Fagan AM, Schindler SE, Cruchaga C, Butt OH, Morris JC, Tarr PI, Ances BM, Dantas G. Ferreiro AL, et al. Sci Transl Med. 2023 Jun 14;15(700):eabo2984. doi: 10.1126/scitranslmed.abo2984. Epub 2023 Jun 14. Sci Transl Med. 2023. PMID: 37315112 Free PMC article.
Alzheimer's disease (AD) pathology is thought to progress from normal cognition through preclinical disease and ultimately to symptomatic AD with cognitive impairment. ...The change in gut microbiome composition correlated with beta-amyloid (Abeta) and tau pathologi …
Alzheimer's disease (AD) pathology is thought to progress from normal cognition through preclinical disease and ultimately to …
Proteomics of brain, CSF, and plasma identifies molecular signatures for distinguishing sporadic and genetic Alzheimer's disease.
Sung YJ, Yang C, Norton J, Johnson M, Fagan A, Bateman RJ, Perrin RJ, Morris JC, Farlow MR, Chhatwal JP, Schofield PR, Chui H, Wang F, Novotny B, Eteleeb A, Karch C, Schindler SE, Rhinn H, Johnson ECB, Oh HS, Rutledge JE, Dammer EB, Seyfried NT, Wyss-Coray T, Harari O, Cruchaga C. Sung YJ, et al. Sci Transl Med. 2023 Jul 5;15(703):eabq5923. doi: 10.1126/scitranslmed.abq5923. Epub 2023 Jul 5. Sci Transl Med. 2023. PMID: 37406134 Free PMC article.
Proteomic studies for Alzheimer's disease (AD) are instrumental in identifying AD pathways but often focus on single tissues and sporadic AD cases. ...Enrichment analyses highlighted several pathways, including those implicated in AD (calcineurin and Apo E), Parkinson's …
Proteomic studies for Alzheimer's disease (AD) are instrumental in identifying AD pathways but often focus on single tissues and spor …
CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer's disease.
Horie K, Salvadó G, Barthélemy NR, Janelidze S, Li Y, He Y, Saef B, Chen CD, Jiang H, Strandberg O, Pichet Binette A, Palmqvist S, Sato C, Sachdev P, Koyama A, Gordon BA, Benzinger TLS, Holtzman DM, Morris JC, Mattsson-Carlgren N, Stomrud E, Ossenkoppele R, Schindler SE, Hansson O, Bateman RJ. Horie K, et al. Nat Med. 2023 Aug;29(8):1954-1963. doi: 10.1038/s41591-023-02443-z. Epub 2023 Jul 13. Nat Med. 2023. PMID: 37443334 Free PMC article.
Aggregated insoluble tau is one of two defining features of Alzheimer's disease. Because clinical symptoms are strongly correlated with tau aggregates, drug development and clinical diagnosis need cost-effective and accessible specific fluid biomarkers of tau aggregates; h …
Aggregated insoluble tau is one of two defining features of Alzheimer's disease. Because clinical symptoms are strongly correlated wi …
Disease staging of Alzheimer's disease using a CSF-based biomarker model.
Salvadó G, Horie K, Barthélemy NR, Vogel JW, Pichet Binette A, Chen CD, Aschenbrenner AJ, Gordon BA, Benzinger TLS, Holtzman DM, Morris JC, Palmqvist S, Stomrud E, Janelidze S, Ossenkoppele R, Schindler SE, Bateman RJ, Hansson O. Salvadó G, et al. Nat Aging. 2024 May;4(5):694-708. doi: 10.1038/s43587-024-00599-y. Epub 2024 Mar 21. Nat Aging. 2024. PMID: 38514824 Free PMC article.
Biological staging of individuals with Alzheimer's disease (AD) may improve diagnostic and prognostic workup of dementia in clinical practice and the design of clinical trials. ...Our analysis involved 426 participants from BioFINDER-2 and was validated in 222 participants …
Biological staging of individuals with Alzheimer's disease (AD) may improve diagnostic and prognostic workup of dementia in clinical …
Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests.
Barthélemy NR, Salvadó G, Schindler SE, He Y, Janelidze S, Collij LE, Saef B, Henson RL, Chen CD, Gordon BA, Li Y, La Joie R, Benzinger TLS, Morris JC, Mattsson-Carlgren N, Palmqvist S, Ossenkoppele R, Rabinovici GD, Stomrud E, Bateman RJ, Hansson O. Barthélemy NR, et al. Nat Med. 2024 Apr;30(4):1085-1095. doi: 10.1038/s41591-024-02869-z. Epub 2024 Feb 21. Nat Med. 2024. PMID: 38382645 Free PMC article.
With the emergence of Alzheimer's disease (AD) disease-modifying therapies, identifying patients who could benefit from these treatments becomes critical. ...Main analyses were focused on individuals with cognitive impairment (mild cognitive impairment and mild deme …
With the emergence of Alzheimer's disease (AD) disease-modifying therapies, identifying patients who could benefit from these …
Validation of Plasma Amyloid-beta 42/40 for Detecting Alzheimer Disease Amyloid Plaques.
Li Y, Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Weiner MW, Shaw LM, Masters CL, Fowler CJ, Trojanowski JQ, Korecka M, Martins RN, Janelidze S, Hansson O, Bateman RJ. Li Y, et al. Neurology. 2022 Feb 15;98(7):e688-e699. doi: 10.1212/WNL.0000000000013211. Epub 2021 Dec 14. Neurology. 2022. PMID: 34906975 Free PMC article.
METHODS: Plasma samples (n = 465) were obtained from 3 large Alzheimer disease (AD) research cohorts in the United States (n = 182), Australia (n = 183), and Sweden (n = 100). ...
METHODS: Plasma samples (n = 465) were obtained from 3 large Alzheimer disease (AD) research cohorts in the United States (n = 182), …
Biomarker-based staging of Alzheimer disease: rationale and clinical applications.
Therriault J, Schindler SE, Salvadó G, Pascoal TA, Benedet AL, Ashton NJ, Karikari TK, Apostolova L, Murray ME, Verberk I, Vogel JW, La Joie R, Gauthier S, Teunissen C, Rabinovici GD, Zetterberg H, Bateman RJ, Scheltens P, Blennow K, Sperling R, Hansson O, Jack CR Jr, Rosa-Neto P. Therriault J, et al. Nat Rev Neurol. 2024 Apr;20(4):232-244. doi: 10.1038/s41582-024-00942-2. Epub 2024 Mar 1. Nat Rev Neurol. 2024. PMID: 38429551 Review.
Disease staging, whereby the spatial extent and load of brain pathology are used to estimate the severity of Alzheimer disease (AD), is pivotal to the gold-standard neuropathological diagnosis of AD. ...Finally, we discuss challenges related to the validation and st …
Disease staging, whereby the spatial extent and load of brain pathology are used to estimate the severity of Alzheimer disease …
High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis.
Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Li Y, Gordon BA, Holtzman DM, Morris JC, Benzinger TLS, Xiong C, Fagan AM, Bateman RJ. Schindler SE, et al. Neurology. 2019 Oct 22;93(17):e1647-e1659. doi: 10.1212/WNL.0000000000008081. Epub 2019 Aug 1. Neurology. 2019. PMID: 31371569 Free PMC article.
Plasma Abeta42/Abeta40 could be used in prevention trials to screen for individuals likely to be amyloid PET-positive and at risk for Alzheimer disease dementia. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that plasma Abeta42/Abeta40 levels accurately …
Plasma Abeta42/Abeta40 could be used in prevention trials to screen for individuals likely to be amyloid PET-positive and at risk for Alzhei …
Novel CSF tau biomarkers can be used for disease staging of sporadic Alzheimer's disease.
Salvadó G, Horie K, Barthélemy NR, Vogel JW, Binette AP, Chen CD, Aschenbrenner AJ, Gordon BA, Benzinger TLS, Holtzman DM, Morris JC, Palmqvist S, Stomrud E, Janelidze S, Ossenkoppele R, Schindler SE, Bateman RJ, Hansson O. Salvadó G, et al. medRxiv [Preprint]. 2023 Jul 16:2023.07.14.23292650. doi: 10.1101/2023.07.14.23292650. medRxiv. 2023. PMID: 37503281 Free PMC article. Preprint.
Biological staging of individuals with Alzheimer's disease (AD) may improve diagnostic and prognostic work-up of dementia in clinical practice and the design of clinical trials. ...Our findings indicate that a common pathophysiologic molecular pathway develops across all A …
Biological staging of individuals with Alzheimer's disease (AD) may improve diagnostic and prognostic work-up of dementia in clinical …
165 results